Your browser is no longer supported. Please, upgrade your browser.
Settings
FOLD [NASD]
Amicus Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.90 Insider Own0.70% Shs Outstand267.46M Perf Week4.75%
Market Cap3.34B Forward P/E- EPS next Y-0.27 Insider Trans-13.57% Shs Float250.66M Perf Month-5.70%
Income-238.60M PEG- EPS next Q-0.03 Inst Own- Short Float9.73% Perf Quarter-2.00%
Sales293.90M P/S11.36 EPS this Y27.90% Inst Trans5.70% Short Ratio9.76 Perf Half Y5.04%
Book/sh1.41 P/B7.98 EPS next Y37.80% ROA-27.70% Target Price17.11 Perf Year-50.29%
Cash/sh1.88 P/C5.99 EPS next 5Y-1.00% ROE-84.60% 52W Range8.60 - 25.39 Perf YTD-51.28%
Dividend- P/FCF- EPS past 5Y2.30% ROI-38.00% 52W High-55.69% Beta1.21
Dividend %- Quick Ratio5.20 Sales past 5Y- Gross Margin87.70% 52W Low30.81% ATR0.59
Employees483 Current Ratio5.40 Sales Q/Q18.00% Oper. Margin-67.80% RSI (14)51.95 Volatility5.21% 5.28%
OptionableYes Debt/Eq1.03 EPS Q/Q23.90% Profit Margin-81.20% Rel Volume1.42 Prev Close11.25
ShortableYes LT Debt/Eq1.03 EarningsNov 09 BMO Payout- Avg Volume2.50M Price11.25
Recom2.40 SMA200.46% SMA501.64% SMA2008.97% Volume0 Change0.00%
Nov-15-21Upgrade Stifel Hold → Buy $12 → $16
Sep-30-21Upgrade JP Morgan Neutral → Overweight $16
Jul-19-21Resumed BTIG Research Buy $15
May-27-21Initiated Needham Hold
May-21-21Initiated UBS Buy $16
Apr-14-21Upgrade Cantor Fitzgerald Neutral → Overweight $17
Mar-02-21Initiated Stifel Hold $13
Feb-12-21Downgrade JP Morgan Overweight → Neutral $19
Feb-12-21Downgrade Cantor Fitzgerald Overweight → Neutral $30 → $17
Dec-28-20Resumed Cantor Fitzgerald Overweight $20 → $30
Dec-10-20Downgrade Citigroup Buy → Neutral $20 → $27
Nov-11-20Initiated Berenberg Hold
Jun-17-20Initiated BTIG Research Buy $19
Feb-04-20Resumed Cantor Fitzgerald Overweight $19 → $20
Nov-12-19Reiterated H.C. Wainwright Buy $18 → $20
Jun-17-19Initiated H.C. Wainwright Buy $18
Jun-05-19Reiterated Cantor Fitzgerald Overweight $20 → $19
Apr-05-19Initiated Janney Buy
Jan-30-19Initiated Cantor Fitzgerald Overweight $20
Oct-29-18Initiated Citigroup Neutral $12
Dec-08-21 09:38AM  
Dec-06-21 11:51AM  
Dec-03-21 07:00AM  
Nov-24-21 07:00AM  
Nov-22-21 07:00AM  
Nov-18-21 07:00AM  
Nov-11-21 07:00AM  
06:42AM  
Nov-10-21 10:42AM  
Nov-09-21 04:00PM  
08:25AM  
07:00AM  
Nov-04-21 11:16AM  
Nov-03-21 09:20AM  
07:00AM  
Oct-28-21 03:06PM  
Oct-27-21 10:02AM  
Oct-26-21 12:05PM  
Oct-23-21 06:08AM  
01:04AM  
Oct-19-21 02:00PM  
10:57AM  
Oct-15-21 08:49AM  
Oct-12-21 05:36AM  
Oct-11-21 10:24AM  
Oct-05-21 12:17PM  
Oct-04-21 05:44PM  
Sep-30-21 12:26PM  
08:18AM  
06:24AM  
Sep-29-21 05:30PM  
03:02PM  
08:13AM  
06:30AM  
06:30AM  
Sep-20-21 07:00AM  
Sep-16-21 08:12AM  
Sep-03-21 07:00AM  
Aug-09-21 12:43PM  
Aug-06-21 12:24PM  
Aug-05-21 07:00PM  
08:35AM  
07:00AM  
Aug-04-21 07:00AM  
Aug-02-21 07:00AM  
Jul-29-21 03:05PM  
Jul-27-21 07:00AM  
Jul-06-21 10:06AM  
Jun-22-21 07:21AM  
06:00AM  
Jun-14-21 07:00AM  
Jun-09-21 11:30AM  
Jun-08-21 07:00AM  
Jun-03-21 06:48AM  
May-29-21 04:00AM  
May-28-21 07:00AM  
May-21-21 07:00AM  
May-11-21 11:55AM  
May-10-21 06:30PM  
09:05AM  
07:00AM  
06:45AM  
May-07-21 07:00AM  
May-06-21 07:00AM  
May-05-21 01:21PM  
07:00AM  
May-03-21 03:01PM  
08:30AM  
07:00AM  
Apr-28-21 07:00AM  
Apr-26-21 07:00AM  
Apr-18-21 05:40AM  
Apr-14-21 12:33PM  
Apr-08-21 10:47AM  
Mar-15-21 07:00AM  
Mar-02-21 12:51PM  
01:30AM  
Mar-01-21 08:35AM  
07:24AM  
07:00AM  
06:30AM  
Feb-26-21 10:10AM  
Feb-18-21 07:00AM  
Feb-17-21 07:00AM  
Feb-12-21 04:22PM  
10:06AM  
07:55AM  
07:19AM  
Feb-11-21 04:01PM  
Feb-08-21 02:30PM  
02:30PM  
Jan-28-21 08:40AM  
Jan-21-21 07:00AM  
Jan-18-21 02:37AM  
Jan-11-21 07:00AM  
Jan-05-21 07:00AM  
Dec-21-20 11:36AM  
Dec-18-20 02:00PM  
Dec-15-20 08:42AM  
Dec-13-20 03:16AM  
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for people living with rare metabolic diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data; gene therapies for Fabry and Pompe diseases, as well as for various types of Batten diseases; enzyme replacement therapies for Pompe diseases; and CDKL5 deficiency disorder product candidates. The company also has additional gene therapies in active preclinical development, including gene therapies for mucopolysaccharidosis type IIIB, as well as a next generation program in mucopolysaccharidosis type IIIA. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Campbell Bradley LChief Operating OfficerDec 01Option Exercise4.3810,51546,056467,783Dec 02 08:42 PM
Campbell Bradley LChief Operating OfficerDec 01Sale11.0010,515115,706457,268Dec 02 08:42 PM
Crowley John FChairman & CEONov 15Option Exercise4.3824,935109,215849,461Nov 17 07:30 PM
Crowley John FChairman & CEONov 15Sale11.7524,935292,951824,526Nov 17 07:30 PM
Crowley John FChairman & CEONov 03Option Exercise3.8227,739105,963852,265Nov 03 06:30 PM
Crowley John FChairman & CEONov 03Sale12.0027,739332,868824,526Nov 03 06:30 PM
Campbell Bradley LChief Operating OfficerNov 01Option Exercise4.3810,51546,056467,783Nov 03 06:29 PM
WHITMAN BURKE WDirectorNov 01Buy10.491,50015,73565,082Nov 03 06:31 PM
Crowley John FChairman & CEONov 01Sale10.807,81984,451824,526Nov 03 06:30 PM
Campbell Bradley LChief Operating OfficerNov 01Sale11.3210,515119,054457,268Nov 03 06:29 PM
Crowley John FChairman & CEOOct 15Option Exercise4.3822,00096,360854,345Oct 18 09:42 PM
Crowley John FChairman & CEOOct 15Sale11.2222,000246,871832,345Oct 18 09:42 PM
Campbell Bradley LChief Operating OfficerOct 01Option Exercise4.3810,51546,056467,783Oct 04 06:58 PM
WHITMAN BURKE WDirectorOct 01Buy9.561,50014,34663,582Oct 04 07:00 PM
Crowley John FChairman & CEOOct 01Sale10.007,50075,000832,345Oct 04 06:59 PM
Campbell Bradley LChief Operating OfficerOct 01Sale10.0010,515105,150457,268Oct 04 06:58 PM
Crowley John FChairman & CEOSep 15Option Exercise4.3822,00096,360861,845Sep 17 05:27 PM
Crowley John FChairman & CEOSep 15Sale11.0822,000243,828839,845Sep 17 05:27 PM
Prout SamanthaPrincipal Accounting OfficerSep 03Option Exercise9.754,92548,00488,095Sep 08 06:42 PM
Crowley John FChairman & CEOSep 03Option Exercise3.735,23819,563845,083Sep 08 06:45 PM
Prout SamanthaPrincipal Accounting OfficerSep 03Sale12.014,92559,16883,170Sep 08 06:42 PM
Crowley John FChairman & CEOSep 03Sale12.025,23862,944839,845Sep 08 06:45 PM
Campbell Bradley LChief Operating OfficerSep 01Option Exercise4.3810,51546,056467,783Sep 07 06:56 PM
WHITMAN BURKE WDirectorSep 01Buy11.411,50017,11562,082Sep 07 06:53 PM
Crowley John FChairman & CEOSep 01Sale11.507,50086,250839,845Sep 07 06:55 PM
Campbell Bradley LChief Operating OfficerSep 01Sale11.5010,515120,905457,268Sep 07 06:56 PM
Prout SamanthaPrincipal Accounting OfficerAug 23Sale11.005,04555,49583,170Aug 25 05:55 PM
Crowley John FChairman & CEOAug 16Option Exercise4.3822,00096,360869,345Aug 18 06:36 PM
Crowley John FChairman & CEOAug 16Sale10.2722,000225,918847,345Aug 18 06:36 PM
Campbell Bradley LChief Operating OfficerAug 05Option Exercise4.3821,02892,103478,296Aug 09 08:19 PM
Crowley John FChairman & CEOAug 05Option Exercise4.3822,00096,360884,345Aug 09 08:21 PM
Campbell Bradley LChief Operating OfficerAug 05Sale10.0221,028210,671457,268Aug 09 08:19 PM
Crowley John FChairman & CEOAug 05Sale10.0337,000371,047847,345Aug 09 08:21 PM
WHITMAN BURKE WDirectorAug 02Buy9.281,50013,92060,582Aug 04 05:12 PM
Crowley John FChairman & CEOJul 12Sale9.3114,885138,652862,345Jul 14 09:08 PM
WHITMAN BURKE WDirectorJul 01Buy9.601,50014,40059,082Jul 14 09:09 PM
Crowley John FChairman & CEOJun 15Option Exercise4.3822,00096,360899,230Jun 17 08:06 PM
Crowley John FChairman & CEOJun 15Sale10.2622,000225,632877,230Jun 17 08:06 PM
Campbell Bradley LChief Operating OfficerJun 07Option Exercise3.2173,110234,659474,618Jun 09 07:30 PM
Crowley John FChairman & CEOJun 07Option Exercise6.3122,000138,913906,730Jun 09 07:31 PM
Crowley John FChairman & CEOJun 07Sale10.0129,500295,192877,230Jun 09 07:31 PM
Campbell Bradley LChief Operating OfficerJun 07Sale10.0110,514105,207457,268Jun 09 07:30 PM
WHITMAN BURKE WDirectorJun 01Buy9.241,50013,86147,467Jun 02 06:26 PM
Bleil Lynn DorseyDirectorMay 25Buy8.7428,605250,00850,310May 27 04:16 PM
RAAB MICHAELDirectorMay 18Option Exercise7.565,63442,59326,634May 20 05:03 PM
Campbell Bradley LChief Operating OfficerMay 03Option Exercise6.4510,51467,815422,536May 05 05:59 PM
MCGLYNN MARGARET GDirectorMay 03Option Exercise7.5110,00075,10037,919May 05 06:01 PM
WHITMAN BURKE WDirectorMay 03Buy10.211,50015,31545,967May 05 06:00 PM
MCGLYNN MARGARET GDirectorMay 03Sale10.2710,000102,70427,919May 05 06:01 PM
Crowley John FChairman & CEOMay 03Sale10.287,50077,089884,730May 05 05:59 PM
Campbell Bradley LChief Operating OfficerMay 03Sale10.2710,514107,970412,022May 05 05:59 PM
Crowley John FChairman & CEOApr 22Sale10.017,68376,898892,230Apr 26 05:37 PM
Crowley John FChairman & CEOApr 15Option Exercise6.4522,000141,900921,913Apr 19 07:21 PM
Crowley John FChairman & CEOApr 15Sale10.0922,000222,086899,913Apr 19 07:21 PM
Campbell Bradley LChief Operating OfficerApr 01Option Exercise6.4510,51467,815389,371Apr 05 06:19 PM
WHITMAN BURKE WDirectorApr 01Buy10.001,50015,00044,467Apr 05 06:15 PM
Crowley John FChairman & CEOApr 01Sale10.007,50075,000821,524Apr 05 06:17 PM
Campbell Bradley LChief Operating OfficerApr 01Sale10.0310,514105,505378,857Apr 05 06:19 PM
Crowley John FChairman & CEOMar 22Sale10.297,68279,061829,024Mar 24 05:11 PM
Crowley John FChairman & CEOMar 15Option Exercise6.4522,000141,900858,706Mar 17 07:11 PM
Crowley John FChairman & CEOMar 15Sale10.7722,000236,988836,706Mar 17 07:11 PM
Quimi DaphneChief Financial OfficerMar 05Option Exercise2.9416,62848,886275,998Mar 09 05:38 PM
Campbell Bradley LChief Operating OfficerMar 01Option Exercise6.4510,51467,815389,371Mar 03 07:03 PM
WHITMAN BURKE WDirectorMar 01Buy12.401,50018,60042,967Mar 03 06:58 PM
Crowley John FChairman & CEOMar 01Sale11.857,50088,881836,706Mar 03 07:04 PM
Campbell Bradley LChief Operating OfficerMar 01Sale11.8410,514124,516378,857Mar 03 07:03 PM
Crowley John FChairman & CEOFeb 22Sale11.987,68292,027844,206Feb 24 05:07 PM
Crowley John FChairman & CEOFeb 16Option Exercise6.4522,000141,900873,888Feb 18 06:48 PM
Crowley John FChairman & CEOFeb 16Sale12.2622,000269,700851,888Feb 18 06:48 PM
Campbell Bradley LChief Operating OfficerFeb 01Option Exercise6.4510,51467,815389,371Feb 03 05:58 PM
WHITMAN BURKE WDirectorFeb 01Buy19.091,50028,63741,467Feb 03 06:00 PM
Crowley John FChairman & CEOFeb 01Sale19.087,500143,077851,888Feb 03 05:59 PM
Campbell Bradley LChief Operating OfficerFeb 01Sale19.0810,514200,571378,857Feb 03 05:58 PM
Crowley John FChairman & CEOJan 20Sale21.5150,0001,075,325859,388Jan 20 06:14 PM
Crowley John FChairman & CEOJan 15Option Exercise6.4522,000141,900931,388Jan 20 06:14 PM
Crowley John FChairman & CEOJan 15Sale22.2422,000489,368909,388Jan 20 06:14 PM
Campbell Bradley LChief Operating OfficerJan 04Option Exercise6.4510,51467,815316,847Jan 05 07:40 PM
WHITMAN BURKE WDirectorJan 04Buy23.171,50034,75539,967Jan 05 07:31 PM
Crowley John FChairman & CEOJan 04Sale22.177,500166,305745,429Jan 05 08:07 PM
Campbell Bradley LChief Operating OfficerJan 04Sale22.1710,514233,125306,333Jan 05 07:40 PM
Quimi DaphneChief Financial OfficerDec 21Option Exercise2.945,00014,700249,344Dec 23 05:45 PM
Quimi DaphneChief Financial OfficerDec 21Sale24.095,000120,474244,344Dec 23 05:45 PM
Quimi DaphneChief Financial OfficerDec 15Option Exercise3.2730,32199,222248,500Dec 17 04:32 PM
Campbell Bradley LChief Operating OfficerDec 15Option Exercise5.4520,828113,597359,592Dec 17 04:31 PM
Crowley John FChairman & CEODec 15Option Exercise6.4522,000141,900845,513Dec 16 05:16 PM
Crowley John FChairman & CEODec 15Sale23.9122,000526,101823,513Dec 16 05:16 PM
Do HungChief Science OfficerDec 14Sale23.88111,1252,653,276409,682Dec 16 05:15 PM